article · Pharmaceutics
Background/Objectives: Commercially available drug-eluting stents still suffer from poor blood compatibility, polymer coating delamination, polymer cracking and lack of stability during and after stent implantation that led to adverse events such as stent thrombosis and in-stent restenosis. This article highlights the advantages of using silicon nanofilament (SiNf) as an interface between stent surface and drug-in-polymer coating or bloodstream. Methods: Thin layer of SiNf was successfully formed on the surface of Co-Cr substrate via one-step simple method. For stent applications, sirolimus-in-poly(D,L-lactide) (PDLLA/SRL) matrix was coated on control and SiNf-modified Co-Cr substrates and the stability, cracking, and long-term degradation was compared. Blood compatibility studies were also compared between control and SiNf-modified Co-Cr substrates. Results: The morphology of the filaments showed nanosized structures with nano-gaps between the filaments which support mechanical interlocking of PDLLA/SRL coating and enhanced the coating stability with no coating delamination whereas, the control substrate presented 97% of coating delamination. The PDLLA/SRL coating on stent platform demonstrates smooth and uniform morphology without webbing between stent struts. After stent ballooning, the control stent presented cracking and peeling of the polymer coating from the surface whereas, the SiNf-modified stent did not show any signs of these unfavorable defects. Moreover, SiNf-modified surface showed reduced fibrinogen adsorption and lower number of platelet adhesion with round shape morphology. Conclusions: Overall, this suggests that modifying the metallic substrates with SiNf could act as a universal coating for reinforcing the polymer coating stability, prevent coating defects that accompany stent ballooning, and improve the blood compatibility of the material surfaces that could have various applications to medical implants and devices.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.3390/pharmaceutics18040506
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.